The Joint Stock Earnings Reports

The Joint reported solid Q1 2026 results and major progress on its Joint 2.0 transformation. Key financials: revenue from continuing operations +13% y/y to $14.8M, adjusted EBITDA from continuing operations $2.2M (vs. $46k prior year), net income from continuing operations $1.1M (vs. loss prior year), improved operating cash flow and free cash flow. The company signed transactions that will reduce company-owned/managed clinics from 135 at the start of the initiative to just 3 once pending refranchising deals close, effectively making The Joint a capital-light pure-play franchisor. Management is implementing pricing increases ( $5–$10 implemented across ~300 clinics, $10 favored going forward), national marketing and SEO/AI improvements, new product/offering tests (3-month minimums, Align One plan, CareCredit rollout), and RD territory buybacks. System-wide sales and comps remain pressured (system-wide sales down ~4.9%; Q1 comp sales -4.2%), but management reports four consecutive months of month-over-month improvement in active member counts and sees comps improving through the year (slightly negative Q2, positive Q3–Q4). The company reiterated full-year 2026 guidance: system-wide sales $519M–$552M, comp sales -3% to +3%, consolidated adjusted EBITDA $12.5M–$13.5M, and 30–35 new franchise clinic openings (net clinic count expected lower due to closures). Management expects to realize the benefits of the pure franchisor model in the back half of 2026 with target mid-2026 operating metrics (adjusted EBITDA margin ~19–21%, net income margin ~13–15%, free cash flow conversion ~60–70%). Capital allocation priorities remain growth investments, opportunistic RD buybacks and share repurchases (137k shares repurchased in Q1; $4.5M remains under current authorization).